Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|July 16, 2025

Enhancing CDMO Capabilities to Meet Evolving Client Needs

Rentschler Biopharma is evolving its CDMO capabilities through strategic partnerships, infrastructure investments, and sustainability initiatives to better support clients' complex biologics programs.

Contract development and manufacturing organizations (CDMOs) play an increasingly vital role in the biopharmaceutical industry—evolving from simple capacity providers to strategic, integrated partners. As biopharma pipelines grow more complex and patient needs become more individualized, CDMOs like Rentschler Biopharma are continuously innovating to support clients in bringing life-changing therapies to market quickly, safely, and sustainably.

Watch this video and learn more about:

  • How CDMOs are shifting from service providers to strategic partners with deep expertise and integrated support for complex programs.
  • Investing in infrastructure to achieve scalability and how targeted expansions help meet client needs from clinical to commercial production.
  • Ways in which environmental initiatives create added value for clients and patients in addition to improved sustainability.

Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.